![Francisco J. Esteva: Congratulations to Giuseppe Curigliano for the presentation of the DESTINY-Breast06 trial at ASCO24](https://oncodaily.com/pub/uploads/2024/05/0ba7495df7174543816331780c070d94-e1717583030333.jpg)
Photo from Giuseppe Curigliano/X
Jun 5, 2024, 05:51
Francisco J. Esteva: Congratulations to Giuseppe Curigliano for the presentation of the DESTINY-Breast06 trial at ASCO24
Francisco J. Esteva, Chief of the Division of Hematology and Medical Oncology at Lenox Hill Hospital, shared on LinkedIn: .
“Congratulations to Giuseppe Curigliano for the outstanding presentation of the DESTINY-Breast06 trial at the ASCO Annual Meeting.
The improvement in progression-free survival in the group of patients treated with trastuzumab deruxtecan (T-DXd, Enhertu) compared to conventional chemotherapy is statistically significant and clinically meaningful.
Practice changing study!”
Source: Francisco J. Esteva/LinkedIn